Centrul Medical de Nefrologie si Dializa Diaverum Craiova

The medical center is at the forefront of cardiovascular research specifically targeting patients with end-stage kidney disease (ESKD). This research is crucial as it addresses the intersection of atherosclerotic cardiovascular disease and renal failure, a combination that significantly impacts patient outcomes.

• Innovative therapeutic approaches
• Reduction of inflammatory markers
• Improvement of cardiovascular outcomes

Through the study of CSL300 (Clazakizumab), the center is pioneering efforts to reduce high-sensitivity C-reactive protein (hs-CRP) levels, a key inflammatory marker, thereby potentially improving the quality of life and survival rates of patients undergoing maintenance dialysis.